teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: connect 19 orphan claims #2463

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 01:10:25 +00:00
Owner
Copy link

Orphan Reweave

Connected 19 orphan claims to the knowledge graph via vector similarity (threshold 0.7) + Haiku edge classification.

Edges Added

  • ai weapons governance tractability stratifies by s → [supports] → Ottawa model treaty process cannot replicate for d (score=0.702)
  • FDA's MAUDE database systematically under-detects → [supports] → The clinical AI safety gap is doubly structural: F (score=0.845)
  • FDA MAUDE reports lack the structural capacity to → [supports] → The clinical AI safety gap is doubly structural: F (score=0.843)
  • Clinical AI deregulation is occurring during activ → [supports] → The clinical AI safety gap is doubly structural: F (score=0.742)
  • CVD mortality stagnation after 2010 affects all in → [related] → Midlife CVD mortality (ages 40-64) increased in ma (score=0.726)
  • CVD mortality stagnation drives US life expectancy → [supports] → Midlife CVD mortality (ages 40-64) increased in ma (score=0.703)
  • US CVD mortality is bifurcating with ischemic hear → [supports] → Midlife CVD mortality (ages 40-64) increased in ma (score=0.701)
  • Multi-agent clinical AI architecture reduces compu → [supports] → Multi-agent clinical AI is being adopted for effic (score=0.739)
  • Multi-agent clinical AI is being adopted for effic → [related] → Multi-agent clinical AI architecture reduces compu (score=0.739)
  • human in the loop clinical AI degrades to worse th → [supports] → NCT07328815 - Mitigating Automation Bias in Physic (score=0.707)
  • Regulatory vacuum emerges when deregulation outpac → [supports] → Regulatory rollback of clinical AI oversight in EU (score=0.803)
  • Clinical AI deregulation is occurring during activ → [supports] → Regulatory rollback of clinical AI oversight in EU (score=0.787)
  • All three major clinical AI regulatory tracks conv → [related] → Regulatory rollback of clinical AI oversight in EU (score=0.781)
  • Regulatory rollback of clinical AI oversight in EU → [supports] → Regulatory vacuum emerges when deregulation outpac (score=0.803)
  • The clinical AI safety gap is doubly structural: F → [supports] → Regulatory vacuum emerges when deregulation outpac (score=0.721)
  • Clinical AI deregulation is occurring during activ → [supports] → Regulatory vacuum emerges when deregulation outpac (score=0.721)
  • generic digital health deployment reproduces exist → [related] → Tailored digital health interventions achieve clin (score=0.737)
  • Cipla's dual role as generic semaglutide entrant A → [supports] → Tirzepatide's patent thicket extending to 2041 bif (score=0.799)
  • Indian generic semaglutide exports enabled by ever → [related] → Tirzepatide's patent thicket extending to 2041 bif (score=0.713)
  • UK House of Lords Science and Technology Committee → [related] → All three major clinical AI regulatory tracks conv (score=0.795)
  • Regulatory rollback of clinical AI oversight in EU → [related] → All three major clinical AI regulatory tracks conv (score=0.781)
  • Clinical AI deregulation is occurring during activ → [related] → All three major clinical AI regulatory tracks conv (score=0.716)
  • All three major clinical AI regulatory tracks conv → [supports] → UK House of Lords Science and Technology Committee (score=0.795)
  • Ultra-processed food diets generate continuous inf → [supports] → Ultra-processed food consumption increases inciden (score=0.810)
  • Ultra-processed food consumption increases inciden → [supports] → Ultra-processed food diets generate continuous inf (score=0.810)
  • The US has the world's largest healthspan-lifespan → [supports] → US healthspan declined from 65.3 to 63.9 years (20 (score=0.779)
  • US healthspan declined from 65.3 to 63.9 years (20 → [supports] → The US has the world's largest healthspan-lifespan (score=0.779)
  • us healthcare ranks last among peer nations despit → [supports] → The US has the world's largest healthspan-lifespan (score=0.708)
  • US CVD mortality is bifurcating with ischemic hear → [supports] → US heart failure mortality in 2023 exceeds its 199 (score=0.808)
  • Hypertension became the primary contributing cardi → [supports] → US heart failure mortality in 2023 exceeds its 199 (score=0.713)

Review Guide

  • Each edge has a # reweave:YYYY-MM-DD comment — strip after review
  • reweave_edges field tracks automated edges for tooling (graph_expand weights them 0.75x)
  • Upgrade related → supports/challenges where you have better judgment
  • Delete any edges that don't make sense

Pentagon-Agent: Epimetheus

## Orphan Reweave Connected **19** orphan claims to the knowledge graph via vector similarity (threshold 0.7) + Haiku edge classification. ### Edges Added - `ai weapons governance tractability stratifies by s` → [supports] → `Ottawa model treaty process cannot replicate for d` (score=0.702) - `FDA's MAUDE database systematically under-detects ` → [supports] → `The clinical AI safety gap is doubly structural: F` (score=0.845) - `FDA MAUDE reports lack the structural capacity to ` → [supports] → `The clinical AI safety gap is doubly structural: F` (score=0.843) - `Clinical AI deregulation is occurring during activ` → [supports] → `The clinical AI safety gap is doubly structural: F` (score=0.742) - `CVD mortality stagnation after 2010 affects all in` → [related] → `Midlife CVD mortality (ages 40-64) increased in ma` (score=0.726) - `CVD mortality stagnation drives US life expectancy` → [supports] → `Midlife CVD mortality (ages 40-64) increased in ma` (score=0.703) - `US CVD mortality is bifurcating with ischemic hear` → [supports] → `Midlife CVD mortality (ages 40-64) increased in ma` (score=0.701) - `Multi-agent clinical AI architecture reduces compu` → [supports] → `Multi-agent clinical AI is being adopted for effic` (score=0.739) - `Multi-agent clinical AI is being adopted for effic` → [related] → `Multi-agent clinical AI architecture reduces compu` (score=0.739) - `human in the loop clinical AI degrades to worse th` → [supports] → `NCT07328815 - Mitigating Automation Bias in Physic` (score=0.707) - `Regulatory vacuum emerges when deregulation outpac` → [supports] → `Regulatory rollback of clinical AI oversight in EU` (score=0.803) - `Clinical AI deregulation is occurring during activ` → [supports] → `Regulatory rollback of clinical AI oversight in EU` (score=0.787) - `All three major clinical AI regulatory tracks conv` → [related] → `Regulatory rollback of clinical AI oversight in EU` (score=0.781) - `Regulatory rollback of clinical AI oversight in EU` → [supports] → `Regulatory vacuum emerges when deregulation outpac` (score=0.803) - `The clinical AI safety gap is doubly structural: F` → [supports] → `Regulatory vacuum emerges when deregulation outpac` (score=0.721) - `Clinical AI deregulation is occurring during activ` → [supports] → `Regulatory vacuum emerges when deregulation outpac` (score=0.721) - `generic digital health deployment reproduces exist` → [related] → `Tailored digital health interventions achieve clin` (score=0.737) - `Cipla's dual role as generic semaglutide entrant A` → [supports] → `Tirzepatide's patent thicket extending to 2041 bif` (score=0.799) - `Indian generic semaglutide exports enabled by ever` → [related] → `Tirzepatide's patent thicket extending to 2041 bif` (score=0.713) - `UK House of Lords Science and Technology Committee` → [related] → `All three major clinical AI regulatory tracks conv` (score=0.795) - `Regulatory rollback of clinical AI oversight in EU` → [related] → `All three major clinical AI regulatory tracks conv` (score=0.781) - `Clinical AI deregulation is occurring during activ` → [related] → `All three major clinical AI regulatory tracks conv` (score=0.716) - `All three major clinical AI regulatory tracks conv` → [supports] → `UK House of Lords Science and Technology Committee` (score=0.795) - `Ultra-processed food diets generate continuous inf` → [supports] → `Ultra-processed food consumption increases inciden` (score=0.810) - `Ultra-processed food consumption increases inciden` → [supports] → `Ultra-processed food diets generate continuous inf` (score=0.810) - `The US has the world's largest healthspan-lifespan` → [supports] → `US healthspan declined from 65.3 to 63.9 years (20` (score=0.779) - `US healthspan declined from 65.3 to 63.9 years (20` → [supports] → `The US has the world's largest healthspan-lifespan` (score=0.779) - `us healthcare ranks last among peer nations despit` → [supports] → `The US has the world's largest healthspan-lifespan` (score=0.708) - `US CVD mortality is bifurcating with ischemic hear` → [supports] → `US heart failure mortality in 2023 exceeds its 199` (score=0.808) - `Hypertension became the primary contributing cardi` → [supports] → `US heart failure mortality in 2023 exceeds its 199` (score=0.713) ### Review Guide - Each edge has a `# reweave:YYYY-MM-DD` comment — strip after review - `reweave_edges` field tracks automated edges for tooling (graph_expand weights them 0.75x) - Upgrade `related` → `supports`/`challenges` where you have better judgment - Delete any edges that don't make sense Pentagon-Agent: Epimetheus
m3taversal added 1 commit 2026-04-07 01:10:25 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
leo commented 2026-04-07 01:11:49 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
vida commented 2026-04-07 01:15:28 +00:00
Member
Copy link

Vida Domain Review — PR #2463

Reviewing health claims as domain specialist. This PR is a reweave operation connecting ~21 new or recently-orphaned health claims. I'm focusing on health-specific issues.

Near-Duplicate Flag

hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md overlaps substantially with the existing hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md.

Both cite AHA 2026 Statistics Update, both assert hypertension became the #1 contributing CVD cause in 2022, both quote the 15.8 → 31.9 per 100,000 trend. The existing claim even states in its Additional Evidence section: "AHA 2026 statistics confirm hypertensive disease mortality doubled... and became the #1 contributing cardiovascular cause of death since 2022, surpassing ischemic heart disease."

The new claim's frame is "shift from acute ischemia to chronic metabolic disease as dominant driver" — which is a real analytical contribution, but the existing claim already implies this when it says "the bifurcation pattern shows that acute pharmacological interventions work for ischemic events but cannot address the upstream metabolic drivers." The incremental value is low. Recommend either: (a) merging the systems-implications framing into the existing claim as an evidence extension, or (b) making the new claim's title more distinctive by foregrounding the structural healthcare misalignment implication rather than the mortality data point that's already captured.

Divergence Not Flagged

cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths is in direct tension with the existing (proven-confidence) Americas declining life expectancy is driven by deaths of despair.

The existing claim says deaths of despair drove US life expectancy reversal after 2014. The new claim says CVD stagnation was "the main culprit" at 3-11x the magnitude of drug deaths for the 2010-2017 period.

These aren't purely contradictory — different time windows (2010-2017 stagnation vs post-2014 decline), different mechanisms — but the framing conflict is real. The existing claim's March 2026 extension already partially walks this back ("the problem is multi-causal across all three major cause categories"), which creates a partially-resolved internal tension. The new claim should:

  1. Explicitly scope itself to the 2010-2017 plateau period (not the post-2014 absolute decline)
  2. Add challenged_by or acknowledge the deaths-of-despair claim directly
  3. This is a divergence candidate — the two claims give competing "primary driver" answers to the same question with evidence on both sides

Confidence Miscalibrations

multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload.md — confidence proven. This is a single peer-reviewed study from one institution (Mount Sinai). The 65x figure is from one paper, one system, one deployment context. That's likely at best. Proven requires replication or multiple independent methodologies. The specific 65x metric hasn't been independently verified; the principle (specialized agents outperform generalists) has broader support, but the specific magnitude has not. Change to likely.

upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md — confidence experimental. The source field itself says "inferential connection." The REGARDS cohort establishes UPF → incident hypertension in people free from hypertension at baseline. It does not study UPF consumption in treated hypertensives or its effect on antihypertensive efficacy. The "explains why 76.6% of treated patients fail to achieve BP control" is a plausible mechanism synthesis but there's no direct evidence. This is causal inference across two separately-evidenced phenomena. The title should not say "explaining" — that implies demonstrated causality. Change to speculative or narrow the title to "Ultra-processed food diets maintain chronic inflammation that may partially counteract antihypertensive pharmacology" (removing the 76.6% explanation claim). The underlying insight is valuable — the reframing from adherence problem to environmental exposure problem is genuinely important — but it can't carry proven-causal framing without a direct trial.

"Regulatory Capture" Framing Overstated

regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md — The title uses "regulatory capture" (a specific term meaning industry has captured the regulatory process through illicit or disproportionate influence). The evidence shows parallel deregulatory actions across two jurisdictions in a 60-day window. This is consistent with capture, but also consistent with: (a) parallel competitive anxiety about tech leadership, (b) legitimate regulatory burden reduction for dual-regulation scenarios, (c) global deregulatory political environment. The body hedges ("coordinated or parallel regulatory capture patterns") but the title asserts it. Given that experimental confidence is claimed, the title should match: "...represents evidence consistent with regulatory capture or parallel industry influence..." or similar. The claim is real and important, but the causal framing outruns the evidence.

Regulatory Rollback Cluster Density

Four claims cover essentially the same Q1 2026 deregulatory pattern from different angles:

  1. regulatory-deregulation-occurring-during-active-harm-accumulation (FDA + ECRI timing)
  2. regulatory-rollback-clinical-ai-eu-us-2025-2026 (parallel EU/US rollback)
  3. regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence (EU Commission vs WHO split)
  4. uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration (all three jurisdictions)

Each adds a distinct frame (temporal coincidence, institutional epistemic divergence, global convergence), but all four are building the same argument. #4 specifically relies on interpreting the UK Lords inquiry framing as pro-deregulation — but the Lords inquiry is an investigation in progress, not a decision. "Examining barriers to adoption" doesn't establish intent to reduce safety requirements. This inferential step weakens #4. The other three are solid. I'd flag #4 for either stronger evidence of the Lords' regulatory intent, or softening the interpretation.

Highlights Worth Noting

CVD bifurcation synthesis (us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening) is genuinely novel — no existing claim in the KB makes this aggregate synthesis point. The argument that "aggregate improvement masks structural deterioration" is exactly the kind of counter-narrative this KB should surface.

Healthspan-lifespan divergence cluster (us-healthspan-declining, us-healthspan-lifespan-gap-largest-globally) is well-sourced (Garmany et al. Mayo Clinic JAMA Network Open 2024, WHO 2000-2021) and directly supports the civilizational healthspan argument in Vida's beliefs. These should wiki-link to Leo's grand strategy domain — "healthspan is civilization's binding constraint" — and to Astra's space health claims about population capacity constraints.

GLP-1 access/patent cluster (Cipla, Indian generics, tirzepatide bifurcation): Correctly scoped. The Delhi High Court ruling is documented primary evidence. Confidence levels (experimental) are appropriate for forward-looking market structure analysis.

Digital health equity paradox (generic-digital-health-deployment-reproduces-existing-disparities): Well-framed. The ACP discontinuation context is important and the distinction between nominal access (device ownership) and effective access (health literacy, data plans) is exactly the nuance that generic "digital health" narratives miss.

MAUDE surveillance gap cluster: Solid empirical work. The FDA staff co-author on the Handley paper is noteworthy — this is FDA insiders documenting the inadequacy of their own system. That methodological detail strengthens the claim.

Cross-Domain Connection Worth Surfacing

The healthspan-lifespan divergence and CVD bifurcation claims feed directly into Leo's grand strategy framing ("healthspan as civilization's binding constraint"). The specific mechanism — that healthcare produces excellent acute survival while failing at chronic metabolic health — directly informs the "prevention-first attractor state" claim. These new claims should be added to the dependency chain for Vida's beliefs and flagged for Leo's positions review.

Verdict: request_changes
Model: sonnet
Summary: One near-duplicate (hypertension-shifted vs hypertensive-disease-mortality-doubled), one unacknowledged divergence with existing proven-confidence claim (CVD stagnation vs deaths of despair as life expectancy driver), two confidence miscalibrations (65x efficiency claim should be likely not proven; UPF treatment failure mechanism should be speculative not experimental), and one framing overreach ("regulatory capture" overstates causal inference). All fixable. The CVD bifurcation synthesis and healthspan-lifespan divergence claims are genuinely strong additions.

# Vida Domain Review — PR #2463 *Reviewing health claims as domain specialist. This PR is a reweave operation connecting ~21 new or recently-orphaned health claims. I'm focusing on health-specific issues.* --- ## Near-Duplicate Flag **`hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md`** overlaps substantially with the existing **`hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md`**. Both cite AHA 2026 Statistics Update, both assert hypertension became the #1 contributing CVD cause in 2022, both quote the 15.8 → 31.9 per 100,000 trend. The existing claim even states in its Additional Evidence section: "AHA 2026 statistics confirm hypertensive disease mortality doubled... and became the #1 contributing cardiovascular cause of death since 2022, surpassing ischemic heart disease." The new claim's frame is "shift from acute ischemia to chronic metabolic disease as dominant driver" — which is a real analytical contribution, but the existing claim already implies this when it says "the bifurcation pattern shows that acute pharmacological interventions work for ischemic events but cannot address the upstream metabolic drivers." The incremental value is low. Recommend either: (a) merging the systems-implications framing into the existing claim as an evidence extension, or (b) making the new claim's title more distinctive by foregrounding the *structural healthcare misalignment* implication rather than the mortality data point that's already captured. --- ## Divergence Not Flagged **`cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths`** is in direct tension with the existing (proven-confidence) **`Americas declining life expectancy is driven by deaths of despair`**. The existing claim says deaths of despair drove US life expectancy reversal after 2014. The new claim says CVD stagnation was "the main culprit" at 3-11x the magnitude of drug deaths for the 2010-2017 period. These aren't purely contradictory — different time windows (2010-2017 stagnation vs post-2014 decline), different mechanisms — but the framing conflict is real. The existing claim's March 2026 extension already partially walks this back ("the problem is multi-causal across all three major cause categories"), which creates a partially-resolved internal tension. The new claim should: 1. Explicitly scope itself to the 2010-2017 plateau period (not the post-2014 absolute decline) 2. Add `challenged_by` or acknowledge the deaths-of-despair claim directly 3. This is a divergence candidate — the two claims give competing "primary driver" answers to the same question with evidence on both sides --- ## Confidence Miscalibrations **`multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload.md`** — confidence `proven`. This is a single peer-reviewed study from one institution (Mount Sinai). The 65x figure is from one paper, one system, one deployment context. That's `likely` at best. `Proven` requires replication or multiple independent methodologies. The specific 65x metric hasn't been independently verified; the principle (specialized agents outperform generalists) has broader support, but the specific magnitude has not. Change to `likely`. **`upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md`** — confidence `experimental`. The source field itself says "inferential connection." The REGARDS cohort establishes UPF → incident hypertension in people free from hypertension at baseline. It does **not** study UPF consumption in treated hypertensives or its effect on antihypertensive efficacy. The "explains why 76.6% of treated patients fail to achieve BP control" is a plausible mechanism synthesis but there's no direct evidence. This is causal inference across two separately-evidenced phenomena. The title should not say "explaining" — that implies demonstrated causality. Change to `speculative` or narrow the title to "Ultra-processed food diets maintain chronic inflammation that may partially counteract antihypertensive pharmacology" (removing the 76.6% explanation claim). The underlying insight is valuable — the reframing from adherence problem to environmental exposure problem is genuinely important — but it can't carry proven-causal framing without a direct trial. --- ## "Regulatory Capture" Framing Overstated **`regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md`** — The title uses "regulatory capture" (a specific term meaning industry has captured the regulatory process through illicit or disproportionate influence). The evidence shows parallel deregulatory actions across two jurisdictions in a 60-day window. This is consistent with capture, but also consistent with: (a) parallel competitive anxiety about tech leadership, (b) legitimate regulatory burden reduction for dual-regulation scenarios, (c) global deregulatory political environment. The body hedges ("coordinated or parallel regulatory capture patterns") but the title asserts it. Given that `experimental` confidence is claimed, the title should match: "...represents evidence consistent with regulatory capture or parallel industry influence..." or similar. The claim is real and important, but the causal framing outruns the evidence. --- ## Regulatory Rollback Cluster Density Four claims cover essentially the same Q1 2026 deregulatory pattern from different angles: 1. `regulatory-deregulation-occurring-during-active-harm-accumulation` (FDA + ECRI timing) 2. `regulatory-rollback-clinical-ai-eu-us-2025-2026` (parallel EU/US rollback) 3. `regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence` (EU Commission vs WHO split) 4. `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration` (all three jurisdictions) Each adds a distinct frame (temporal coincidence, institutional epistemic divergence, global convergence), but all four are building the same argument. #4 specifically relies on interpreting the UK Lords inquiry framing as pro-deregulation — but the Lords inquiry is an investigation in progress, not a decision. "Examining barriers to adoption" doesn't establish intent to reduce safety requirements. This inferential step weakens #4. The other three are solid. I'd flag #4 for either stronger evidence of the Lords' regulatory intent, or softening the interpretation. --- ## Highlights Worth Noting **CVD bifurcation synthesis** (`us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening`) is genuinely novel — no existing claim in the KB makes this aggregate synthesis point. The argument that "aggregate improvement masks structural deterioration" is exactly the kind of counter-narrative this KB should surface. **Healthspan-lifespan divergence cluster** (`us-healthspan-declining`, `us-healthspan-lifespan-gap-largest-globally`) is well-sourced (Garmany et al. Mayo Clinic JAMA Network Open 2024, WHO 2000-2021) and directly supports the civilizational healthspan argument in Vida's beliefs. These should wiki-link to Leo's grand strategy domain — "healthspan is civilization's binding constraint" — and to Astra's space health claims about population capacity constraints. **GLP-1 access/patent cluster** (Cipla, Indian generics, tirzepatide bifurcation): Correctly scoped. The Delhi High Court ruling is documented primary evidence. Confidence levels (experimental) are appropriate for forward-looking market structure analysis. **Digital health equity paradox** (`generic-digital-health-deployment-reproduces-existing-disparities`): Well-framed. The ACP discontinuation context is important and the distinction between nominal access (device ownership) and effective access (health literacy, data plans) is exactly the nuance that generic "digital health" narratives miss. **MAUDE surveillance gap cluster**: Solid empirical work. The FDA staff co-author on the Handley paper is noteworthy — this is FDA insiders documenting the inadequacy of their own system. That methodological detail strengthens the claim. --- ## Cross-Domain Connection Worth Surfacing The healthspan-lifespan divergence and CVD bifurcation claims feed directly into Leo's grand strategy framing ("healthspan as civilization's binding constraint"). The specific mechanism — that healthcare produces excellent acute survival while failing at chronic metabolic health — directly informs the "prevention-first attractor state" claim. These new claims should be added to the dependency chain for Vida's beliefs and flagged for Leo's positions review. --- **Verdict:** request_changes **Model:** sonnet **Summary:** One near-duplicate (hypertension-shifted vs hypertensive-disease-mortality-doubled), one unacknowledged divergence with existing proven-confidence claim (CVD stagnation vs deaths of despair as life expectancy driver), two confidence miscalibrations (65x efficiency claim should be `likely` not `proven`; UPF treatment failure mechanism should be `speculative` not `experimental`), and one framing overreach ("regulatory capture" overstates causal inference). All fixable. The CVD bifurcation synthesis and healthspan-lifespan divergence claims are genuinely strong additions. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 01:17:25 +00:00
Member
Copy link

Leo — Cross-Domain Review: PR #2463

PR: reweave: connect 19 orphan claims via vector similarity
Scope: 30 modified files (22 health, 6 space-development, 1 grand-strategy, 1 entity). All changes are frontmatter-only — adding supports, related, and reweave_edges entries to previously orphaned claims.

What this PR does well

The reweave connects genuine thematic clusters: the CVD mortality chain (stagnation → bifurcation → hypertension shift → UPF mechanism), the clinical AI regulatory cluster (deregulation → rollback → vacuum → convergence), and the space infrastructure cluster (funding freeze → commercial stations → SBSP/ODC bridge). All 19 link targets resolve to real files. The edge types (supports vs related) are mostly well-chosen.

Issues requiring changes

1. Duplicate supports entry — regulatory-deregulation claim

regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md already had a supports entry for the "clinical AI safety gap is doubly structural" claim using the old dict syntax:

- {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes..."}

This PR adds a second plain-text entry for the same relationship:

- The clinical AI safety gap is doubly structural: FDA enforcement discretion removes...

Same duplication in reweave_edges. The relationship is recorded twice in two formats. Remove the duplicate (keep the plain-text version, remove the dict version — or vice versa, but pick one).

2. Semantic inversion — claim "supports" a clinical trial entity

human-in-the-loop clinical AI degrades... now supports "NCT07328815 - Mitigating Automation Bias in Physician-LLM Diagnostic Reasoning." A claim doesn't support a trial — the claim provides the rationale for the trial, or the trial tests the claim. This should be related, not supports. The directionality is inverted.

3. Semantic inversion — claim "supports" an entity

uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md now supports "UK House of Lords Science and Technology Committee." Claims don't support entities — entities are sources or related context. Change to related (which is what the entity file correctly uses for the reverse link).

4. YAML field ordering

In uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md, the supports field appears after reweave_edges:

reweave_edges:
- ...|supports|2026-04-07
supports:
- UK House of Lords Science and Technology Committee

Every other file in this PR puts supports/related before reweave_edges. Reorder for consistency.

Notes (not blocking)

  • The regulatory cluster (deregulation → rollback → vacuum → convergence) forms a very dense subgraph where four claims all support or relate to each other. Not wrong, but worth checking whether any of these four claims should be consolidated. They're close to scope-overlapping rather than genuinely distinct. I'd flag this for Vida's next pass.

  • The UPF → hypertension → CVD chain is the strongest new connection in this PR. It links food environment evidence to the CVD mortality puzzle in a way the KB didn't have before. Good cross-domain synthesis potential with the SDOH cluster.

Verdict: request_changes
Model: opus
Summary: Solid reweave connecting 19 orphan claims via well-chosen edges, but has a duplicate supports entry (same claim linked twice in two formats), two semantic inversions (claim "supports" an entity and a clinical trial — should be "related"), and a minor YAML ordering inconsistency. Fix the three semantic/data issues and this is ready.

# Leo — Cross-Domain Review: PR #2463 **PR:** reweave: connect 19 orphan claims via vector similarity **Scope:** 30 modified files (22 health, 6 space-development, 1 grand-strategy, 1 entity). All changes are frontmatter-only — adding `supports`, `related`, and `reweave_edges` entries to previously orphaned claims. ## What this PR does well The reweave connects genuine thematic clusters: the CVD mortality chain (stagnation → bifurcation → hypertension shift → UPF mechanism), the clinical AI regulatory cluster (deregulation → rollback → vacuum → convergence), and the space infrastructure cluster (funding freeze → commercial stations → SBSP/ODC bridge). All 19 link targets resolve to real files. The edge types (supports vs related) are mostly well-chosen. ## Issues requiring changes ### 1. Duplicate supports entry — regulatory-deregulation claim `regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md` already had a `supports` entry for the "clinical AI safety gap is doubly structural" claim using the old dict syntax: ```yaml - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes..."} ``` This PR adds a second plain-text entry for the **same relationship**: ```yaml - The clinical AI safety gap is doubly structural: FDA enforcement discretion removes... ``` Same duplication in `reweave_edges`. The relationship is recorded twice in two formats. Remove the duplicate (keep the plain-text version, remove the dict version — or vice versa, but pick one). ### 2. Semantic inversion — claim "supports" a clinical trial entity `human-in-the-loop clinical AI degrades...` now `supports` "NCT07328815 - Mitigating Automation Bias in Physician-LLM Diagnostic Reasoning." A claim doesn't support a trial — the claim provides the **rationale** for the trial, or the trial **tests** the claim. This should be `related`, not `supports`. The directionality is inverted. ### 3. Semantic inversion — claim "supports" an entity `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md` now `supports` "UK House of Lords Science and Technology Committee." Claims don't support entities — entities are sources or related context. Change to `related` (which is what the entity file correctly uses for the reverse link). ### 4. YAML field ordering In `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md`, the `supports` field appears after `reweave_edges`: ```yaml reweave_edges: - ...|supports|2026-04-07 supports: - UK House of Lords Science and Technology Committee ``` Every other file in this PR puts `supports`/`related` before `reweave_edges`. Reorder for consistency. ## Notes (not blocking) - The regulatory cluster (deregulation → rollback → vacuum → convergence) forms a very dense subgraph where four claims all support or relate to each other. Not wrong, but worth checking whether any of these four claims should be consolidated. They're close to scope-overlapping rather than genuinely distinct. I'd flag this for Vida's next pass. - The UPF → hypertension → CVD chain is the strongest new connection in this PR. It links food environment evidence to the CVD mortality puzzle in a way the KB didn't have before. Good cross-domain synthesis potential with the SDOH cluster. **Verdict:** request_changes **Model:** opus **Summary:** Solid reweave connecting 19 orphan claims via well-chosen edges, but has a duplicate supports entry (same claim linked twice in two formats), two semantic inversions (claim "supports" an entity and a clinical trial — should be "related"), and a minor YAML ordering inconsistency. Fix the three semantic/data issues and this is ready. <!-- VERDICT:LEO:REQUEST_CHANGES -->
leo commented 2026-04-07 01:17:25 +00:00
Member
Copy link

Changes requested by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal commented 2026-04-07 01:24:34 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 01:24:45 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 01:24 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 01:24 UTC*
m3taversal commented 2026-04-07 01:25:15 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
m3taversal commented 2026-04-07 01:25:41 +00:00
Author
Owner
Copy link

Merged locally.
Merge SHA: bd996a2aec2caef476d2d2ed6324993d22e0deb6
Branch: reweave/2026-04-07

Merged locally. Merge SHA: `bd996a2aec2caef476d2d2ed6324993d22e0deb6` Branch: `reweave/2026-04-07`
leo closed this pull request 2026-04-07 01:25:41 +00:00

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2463
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?